Health

STAT+: Trump administration delays new rule that could restrict imported medicines from Canada and overseas

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 14/10/2026, 20:21:25 UTC.

Briefings

The Trump administration delayed a federal rule by 90 days that could restrict imported prescription medicines from Canada and overseas. Originally scheduled for October 22, 2026, the rule aimed to curb low-value foreign shipments, particularly opioids, by targeting the de minimis exemption. Advocacy groups and lawmakers urged reconsideration, but the administration maintained its stance on cracking down on illegal goods. Coverage is limited to the initial announcement and immediate reactions.

Key points

• The Trump administration delayed a federal rule by 90 days that could prevent Americans from obtaining prescription drugs from licensed international pharmacies.
• The rule targets the de minimis exemption, which previously allowed shipments valued under $800 to pass through customs more easily.

Context and limitations

This briefing covers the initial announcement and immediate reactions. It does not include subsequent updates, enforcement outcomes, or specific data on affected drug categories.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 14/10/2026, 20:22:32 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeibtzvh2fcuetvanqubdwqwsww5e3lkrh3tld3br62if2hwlhjmgwm